A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol

Elizaveta Gribaleva(King's College London), Carsten Flohr(King's College London), Niels Steen Krogh(Synlab Czech (Czechia)), Thomas Werfel(Medizinische Hochschule Hannover), Dmitri Wall(Children's Health Ireland at Crumlin), Simon Francis Thomsen(University of Copenhagen), Ahmet Akkoç(Synlab Czech (Czechia)), Wouter Ouwerkerk(University of Amsterdam), Dan Henrohn(Uppsala University), Louise A. A. Gerbens(Amsterdam UMC Location University of Amsterdam), Abaigeal Jackson(Vhi Healthcare), Ida Vittrup(Leo Pharma (Denmark)), Rayka Malek(King's College London), Lara Cutlar(University College Dublin), G. Fletcher(Cystic Fibrosis Ireland), Bolaji Coker(King's College London), Jochen Schmitt(University Hospital Carl Gustav Carus), Phyllis I. Spuls, Alan D. Irvine(Trinity College Dublin), Thomas Birkner(University Hospital Carl Gustav Carus), Con Hennessy(University College Dublin), Stephan Weidinger(University Hospital Schleswig-Holstein), Ariënna Hyseni(Amsterdam UMC Location University of Amsterdam), Rowena Randall(Pfizer (United Kingdom)), David Prieto-Merino(King's College London), K.T. Chan(St Thomas' Hospital), Erwin Bruninx(Pfizer (United States)), Anne Grete Frøstrup(Pfizer (United Kingdom))
Skin Health and Disease
April 22, 2025
Cited by 1


Related Papers